<DOC>
	<DOCNO>NCT01303315</DOCNO>
	<brief_summary>To assess TANTALUS therapy type 2 diabetic patient tolerate GLP-1 agonist due unacceptable side effect ; assess TANTALUS therapy type 2 diabetic patient sufficiently benefit GLP-1 receptor agonist therapy</brief_summary>
	<brief_title>TANTALUS Therapy Type 2 Diabetic Patients Intolerant Inadequately Responsive GLP-1 Receptor Agonist Therapy</brief_title>
	<detailed_description>The present protocol address whether effect TANTALUS treatment complimentary GLP-1 treatment partially effective whether replace GLP-1 treatment individual tolerate GLP-1 agonist unacceptable side effect . This investigation 3 arm multicenter study enroll Run-In Period 400 type 2 diabetes mellitus . This Run-In Period facilitate screening patient aim maximum 30 patient arm complete Evaluation Period 6 month . The study aim evaluate TANTALUS therapy compare GLP-1 receptor agonist therapy evaluate improvement glycemic control weight 6 month treatment 3 study group , : - Group A : subject GLP-1 receptor agonist therapy - Group B : subject GLP-1 receptor agonist therapy TANTALUS therapy - Group C : subject TANTALUS therapy</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>1 . Male female subject 21 70 year age 2 . Type 2 diabetes duration 6 month le 10 year 3 . 7.8 % &lt; HbA1c &lt; 10.5 % T2DM duration less equal 5 year 4 . 7.8 % &lt; HbA1c &lt; 10.0 % T2DM duration 5 year 5 . BMI &lt; 40 kg/m2 6 . Taking least one oral antidiabetic medication 7 . Patients treat GLP1 receptor agonist least one oral antidiabetic medication may include follow condition : . The HbA1c , GLP1 receptor agonist therapy administer , : . 7.8 % &lt; HbA1c &lt; 10.5 % T2DM duration le 5 year ii . 7.8 % &lt; HbA1c &lt; 10.0 % T2DM duration great 5 year b . The patient GLP1 receptor agonist therapy 12 week 8 . Women childbearing potential ( i.e. , postmenopausal surgically sterilize ) must agree use adequate birth control methods 9 . If subject take lipidlowering medication , treatment must stable least one month prior enrollment 10 . If subject take antihypertensive medication , treatment must stable least one month prior enrollment 11 . If subject take antidepressant medication , treatment must stable least one month prior enrollment 12 . Willingness refrain use prescription , counter , herbal weight loss product duration trial 13 . Ability willingness perform require study data collection procedure adhere operate requirement TANTALUSÂ® System 14 . Alert , mentally competent , able understand willing comply requirement clinical trial , personally motivate abide requirement restriction clinical trial 15 . Able provide voluntary inform consent 1 . Insulin therapy within last 3 month 2 . GLP1 receptor agonist therapy longer 3 month 3 . Diagnosed renal dysfunction history renal dysfunction 4 . Taking medication know affect gastric motility 5 . Use prescription , counter herbal weight loss product obesity drug past two month 6 . Experiencing severe progress diabetic complication ( 7 . Prior wound heal problem 8 . Diagnosed past current psychiatric condition may impair ability comply study procedures 9 . Use antipsychotic medication 10 . Diagnosed eat disorder bulimia binge eat 11 . Obesity due endocrinopathy 12 . Hiatal hernia require surgical repair paraesophageal hernia 13 . Pregnant lactate 14 . Diagnosed impaired liver function 15 . Any prior bariatric surgery 16 . Any history pancreatitis 17 . Any history peptic ulcer disease within 5 year enrollment 18 . Diagnosed Gastroparesis GI motility disorder 19 . Use active medical device ( either implantable external ) ICD , drug infusion device , neurostimulator ( either implant worn ) . Subjects use external active device able willing avoid use device study may enrol . 20 . Cardiac history physician feel exclude subject study . 21 . Use another investigational device agent 30 day prior enrollment 22 . A history lifethreatening disease within 5 year enrollment 23 . Any additional condition ( ) Investigator 's opinion would warrant exclusion study prevent subject completing study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>C19 246 300</keyword>
</DOC>